Tafluprost clinical trials
How each study uses tafluprost is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 10 Feb 2012 · ZIOPTAN · NDA 202514 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 8
Santen Oy (3) · Santen Pharmaceutical (Taiwan) Co., LTD (1) · Aristotle University Of Thessaloniki (1) · Ordination Dr. Hommer (1) · Gangnam Severance Hospital (1) · Dr. Anton Hommer (1) · FinnMedi Oy (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1)
Often tested with
Tested in the same studies.
Latanoprost (2) · Timolol (2) · Dorzolamide (1) · Travoprost (1)
Studies
Open first, then newest update. How each study uses tafluprost is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.Status unknownPhase 4Fondazione G.B. Bietti, IRCCSNCT05299593Written as tafluprost/timololHow we know
- Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)CompletedNot applicableSanten Pharmaceutical (Taiwan) Co., LTDNCT04737928Written as tafluprostHow we know
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined TherapyCompletedPhase 4Aristotle University Of ThessalonikiNCT02802137Written as tafluprostHow we know
- A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film ThicknessCompletedPhase 4Ordination Dr. HommerNCT03204487Written as Tafluprost 15µg/mlHow we know
- Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma PatientsCompletedPhase 4Gangnam Severance HospitalNCT03104621Written as 0.0015% tafluprostHow we know
- Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/mlStatus unknownPhase 4Universitaire Ziekenhuizen KU LeuvenNCT02471105Written as Tafluprost Unit Dose Preservative Free 15microgram/mlHow we know
- An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and MoreCompletedPhase 4Dr. Anton HommerNCT01979913Written as Saflutan® 15 microgram/ml Augentropfen im EinzeldosisbehältnisHow we know
- The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With GlaucomaCompletedPhase 4FinnMedi OyNCT01369771Written as Tafluprost 0.0015%How we know
- Switching From Preserved to Preserved-free Treatments for Glaucoma.Status unknownPhase 3Paolo FogagnoloNCT01433900Written as TafluprostHow we know
- Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye DropsCompletedPhase 3Santen OyNCT01087671Written as tafluprostHow we know
- Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)CompletedPhase 4Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaNCT01162603Written as TAFLUPROST 0.0015% EYEDROPSHow we know
- Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular HypertensionCompletedPhase 4Alcon ResearchNCT00966940Written as Tafluprost 0.0015% ophthalmic solutionHow we know
- Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved FormulationCompletedPhase 3Santen OyNCT00918346Written as Tafluprost 0.0015%How we know
- Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye DropsCompletedPhase 3Santen OyNCT00596791Written as tafluprostHow we know
Given beside what is tested · 1 — tafluprost is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with tafluprost
- A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTCompletedPhase 1/2Santen Inc.NCT01654484Written as 0.0015% tafluprostHow we know
- DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%CompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01342081Written as Tafluprost ophthalmic solution 0.0015%How we know
- Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant AdministrationsCompletedPhase 3Santen OyNCT01306461Written as Timolol and TafluprostHow we know
Codes
What other systems call tafluprost · ClinicalTrials.gg INT004643
- MeSH (NLM) C485333tafluprostOne source NLM
- UNII (FDA) 1O6WQ6T7G3TAFLUPROSTConfirmed FDA, NLM, Wikidata
- RxNorm 1244607Confirmed FDA, Wikidata
- Wikidata Q2139543tafluprostConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87385TafluprostOne source FDA
- DrugBank DB08819One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C485333 | tafluprost | One source NLM |
| UNII (FDA) | 1O6WQ6T7G3 | TAFLUPROST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1244607 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2139543 | tafluprost | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87385 | Tafluprost | One source FDA |
| DrugBank | DB08819 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.